Abstract
The relevance of this topic lies in the lack of reliable statistical data in available literature regarding the incidence of parathyroid gland disorders in pregnant women and the differences in diagnosis and therapy during pregnancy versus outside of pregnancy. A physician’s knowledge of the physiological changes that occur in a woman’s body during pregnancy, including mineral metabolism and endocrine gland function, facilitates accurate and timely differential diagnosis between parathyroid tumors, physiological processes, and symptoms of gestational complications. Differential diagnosis of parathyroid pathology from gestational processes at various stages of pregnancy is complex. Timely detection of parathyroid pathology is particularly important at the stage of pregnancy planning. Differential diagnosis of parathyroid adenoma is carried out in comparison with gestational processes, including gestational complications such as nausea and vomiting in pregnant women. Late diagnosis of clinical manifestations of parathyroid pathology in pregnancy can lead to severe consequences for both the mother and the fetus. For this reason, in clinical practice, timely detection of parathyroid pathology during the pregnancy planning stage is essential. Examination of pregnant women and determination of therapeutic interventions should be multidisciplinary, personalized, and include measurement of blood levels of thyroid-stimulating hormone, vitamin D, calcium, magnesium, phosphorus, and parathyroid hormone. Therapeutic options for hyperparathyroidism in pregnant women are limited. A personalized and multidisciplinary approach is essential in each individual case. Women with parathyroid tumors require individualized, qualified monitoring during both the early and late postpartum periods and during lactation, as there is always a risk of hypercalcemia. Administration of vitamin D should be carried out under laboratory control of its blood levels in pregnant women and should be personalized, taking into account the gestational age. In newborns of mothers with parathyroid tumors, it is necessary to monitor calcium levels in both blood and urine.